Moderna, Inc. (MRNA)
| Market Cap | 10.90B |
| Revenue (ttm) | 3.08B |
| Net Income (ttm) | -2.90B |
| Shares Out | 389.08M |
| EPS (ttm) | -7.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,385,505 |
| Open | 26.97 |
| Previous Close | 26.69 |
| Day's Range | 26.80 - 28.59 |
| 52-Week Range | 23.15 - 91.99 |
| Beta | 1.83 |
| Analysts | Hold |
| Price Target | 46.24 (+65.03%) |
| Earnings Date | Aug 1, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $46.24, which is an increase of 65.03% from the latest price.
News
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop fundi...
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting in...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Rela...
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Moderna cuts 2025 revenue to $2.2B after UK booster delay
Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 ...
Moderna is laying off 10% of its workforce. Does RFK Jr. have anything to do with it?
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on Ju...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Moderna Stock Drops After Earnings Report. What Has Wall Street Worried.
Moderna stock was falling in Friday's premarket after the drugmaker's better-than-expected quarterly results were overshadowed by a cut to the high end of its full-year outlook.
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts.
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Moderna lowered the high end of its 2025 revenue outlook, citing a delay in vaccine shipments to the U.K. The company lost less than Wall Street analysts were expecting for the second quarter and pos...
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reducti...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1.
More than 800 Moderna employees will lose their jobs this year as costs are slashed
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the biotechnology company's plan to cut costs by $1.5 billion over the next couple ...
Moderna to cut 10% of global workforce as Covid shot sales drop 20%
Moderna is reducing its global workforce by around 10% by the end of 2025 as demand for Covid-19 vaccines continues to weaken. The company, which had about 5,800 full-time employees across 18 countrie...
Moderna plans to lay off 10% of workforce to cut costs
Moderna plans to trim roughly 10% of its global workforce by the end of the year to cut costs amid declining sales of its COVID-19 vaccines, the company said on Thursday.
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In ...
Pandemic darlings Moderna, BioNTech are now on two different paths
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA ...
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C...
Moderna Announces Data to be Presented at ESMO Congress 2025
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2...
EU regulator backs Moderna's updated COVID vaccine
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.